Cefuroxime Sodium Injection

[23 September 2015]

Products Affected - Description

Cefuroxime powder for solution for injection, Sagent
1.5 gram, vial, 25 count (NDC 25021-0119-20)
7.5 gram, bulk vial, 10 count (NDC 25021-0120-59)
750 mg, vial, 25 count (NDC 25021-0118-10)

Reason for the Shortage

  • Sagent suspended the manufacture of cefuroxime injection.
  • BBraun, Fresenius Kabi, and Hospira discontinued manufacturing cefuroxime in 2013.

Available Products

Cefuroxime powder for solution for injection, West-Ward
1.5 gram vial, 25 count (NDC 00143-9977-22)
7.5 gram bulk vial, 10 count (NDC 00143-9976-03)
750 mg vial, 25 count (NDC 00143-9979-22)
Zinacef injection, Covis
1.5 gram/50 mL premix, 24 count (NDC 24987-0425-00)
Zinacef powder for solution for injection, Covis
1.5 gram ADD-Vantage vial, 10 count (NDC 24987-0437-00)
1.5 gram vial, 10 count (NDC 24987-0354-10)
7.5 gram bulk vial, 6 count (NDC 24987-0400-00)
750 mg, ADD-Vantage vial, 25 count (NDC 24987-0436-00)
750 mg vial, 10 count (NDC 24987-0352-10)

Estimated Resupply Dates

All currently manufactured products are available.

Related Shortages


September 23, August 12, July 2 and 1, May 22 and 8, April 7 and 6, February 26, January 14, 2015; December 8, October 13, August 26, 13 and 4, July 9, June 25, April 11, March 14, January 15, 2014; December 10, August 27 and 1, July 16, June 6, April 12, March 22 and 8, February 6, January 29 and 25, 2013, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.